Biogen

News

Biogen wields axe again ahead of Leqembi rollout

Biogen has announced another big round of layoffs and cost-cutting, with 1,000 more workers set to lose their jobs after it shed around 900 last year and shelved various R

News

Donanemab data an “important advance” in Alzheimer’s

The full data from the TRAILBLAZER-ALZ 2 trial of Eli Lilly’s amyloid drug donanemab has confirmed the top-line results reported in May, but also

News

Uptake of Leqembi for Alzheimer’s may be slow

Full FDA approval of Eisai and Biogen’s Alzheimer’s disease therapy Leqembi may have unlocked the door to a broader rollout of the drug and potentially blockbuster sales,

News

FDA approves first progression-slowing Alzheimer's drug

Eisai's Leqembi, marketed by Biogen, secured full FDA regulatory approval as expected

News

CMS sheds light on its registry plan for Alzheimer’s drugs

The Centers for Medicare and Medicaid Services (CMS) in the US has provided more details about the controversial plan to require participation in a patient registry as a c

News

FDA panel gives unanimous support to Leqembi

The first full regulatory approval for an amyloid-targeting therapy for Alzheimer’s disease could come within a month, after an expert panel voted 6 to 0 in favour of Eisa

Biogen wields axe again ahead of Leqembi rollout

Donanemab data an “important advance” in Alzheimer’s

Uptake of Leqembi for Alzheimer’s may be slow

FDA approves first progression-slowing Alzheimer's drug

CMS sheds light on its registry plan for Alzheimer’s drugs

FDA panel gives unanimous support to Leqembi

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Biogen

Editor's Picks